COST EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS TREATMENT FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FAILURE OF DOCETAXEL USING DATA FROM REAL LIFE TREATMENT PRAXIS IN SWEDEN

被引：1
|
作者：
Persson, U. [1 ]
Nilsson, S. [2 ]
Prutz, C. [3 ]
Hjortsberg, C. [3 ]
机构：
[1] Swedish Inst Hlth Econ, Lund, Sweden
[2] Dept Oncol Pathol, Stockholm, Sweden
[3] Janssen Cilag AB, Sollentuna, Sweden
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.655
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A134 / A135
页数：2
相关论文
共 50 条
  • [1] ECONOMIC EVALUATION OF ABIRATERONE ACETATE AS TREATMENT FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FAILURE OF DOCETAXEL IN SWEDEN
    Persson, U.
    Nilsson, S.
    Hjortsberg, C.
    Prutz, C.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [2] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN
    Shibahara, H.
    Shiroiwa, T.
    Nakamura, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2013, 16 (07) : A415 - A416
  • [3] Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
    Harland, Stephen
    Staffurth, John
    Molina, Arturo
    Hao, Yanni
    Gagnon, Dennis D.
    Sternberg, Cora N.
    Cella, David
    Fizazi, Karim
    Logothetis, Christopher J.
    Kheoh, Thian
    Haqq, Christopher M.
    de Bono, Johann S.
    Scher, Howard I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (17) : 3648 - 3657
  • [4] Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment
    Aggarwal, Rahul
    Harris, Anna
    Formaker, Carl
    Small, Eric J.
    Molina, Arturo
    Griffin, Thomas W.
    Ryan, Charles J.
    CLINICAL GENITOURINARY CANCER, 2014, 12 (05) : E167 - E172
  • [5] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    M. Koninckx
    J. L. Marco
    I. Pérez
    M. T. Faus
    V. Alcolea
    F. Gómez
    Clinical and Translational Oncology, 2019, 21 : 314 - 323
  • [6] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    Koninckx, M.
    Marco, J. L.
    Perez, I.
    Faus, M. T.
    Alcolea, V.
    Gomez, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (03) : 314 - 323
  • [7] AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY
    Thompson, Melissa
    Li, Tracy
    Todd, Mary Beth
    Yu, Margaret K.
    Kheoh, Thian
    He, Jianming
    Saadi, Ryan
    JOURNAL OF UROLOGY, 2014, 191 (04) : E810 - E810
  • [8] Comparative Study on the Effect of Docetaxel and Abiraterone in the Treatment of Metastatic Castration Resistant Prostate Cancer
    Ma, Liming
    Chen, Shaopeng
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 86 : 70 - 77
  • [9] Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer
    Shameem, Raji
    Hamid, Muhammad Saad
    Xu, Kevin Y.
    Wu, Shenhong
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 64 - 72
  • [10] Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
    Ayşe Demirci
    Cemil Bilir
    Burcu Gülbağcı
    İlhan Hacıbekiroğlu
    İbrahim V. Bayoğlu
    İrem Bilgetekin
    Sinan Koca
    Havva Y. Çınkır
    Nadiye Akdeniz
    Deniz Gül
    Ceyhun Varım
    Umut Demirci
    Berna Öksüzoğlu
    Scientific Reports, 11
12345